Navigation Links
Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants
Date:11/6/2009

QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myriant's biobased Succinic Acid plants based on renewable feedstocks. The execution of this alliance marks an important milestone in Myriant's commercialization of biobased Succinic Acid and exemplifies Uhde's continued commitment to the renewable chemicals industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091021/NE96331LOGO )

Myriant, which has successfully piloted the Succinic Acid process previously together with Uhde, has begun production of ton-sized samples for its customers to verify commercial product specifications and quality. The company expects to begin commercial production of biobased Succinic Acid second half of 2010.

Under Myriant's build-own-operate strategy, the alliance agreement combines the full breadth of Uhde's design and process expertise with Myriant's leading renewable, biobased Succinic Acid technology for the rapid deployment of full-scale commercial facilities. Uhde Corporation of America will be Myriant's engineering contractor for projects located in the U.S.; Uhde GmbH will act as Myriant's EPC Contractor in all other regions of the world. "The addition of Uhde's capabilities and experience is a perfect complement to Myriant's Succinic Acid program," said Stephen Gatto, Myriant Chairman and Chief Executive Officer. "Utilizing Uhde's unsurpassed EPC track record represents the final piece of the puzzle in making the construction of world scale biobased Succinic Acid plants a reality."

With more than 2,000 plants to its credit, Uhde GmbH is one of the world's leading engineering companies in the design and construction of chemical, refining and other industrial plants. "Uhde GmbH has built up special expertise in the field of biotechnology since 2004, and we are very excited about matching that expertise with Myriant's leadership position in Succinic Acid," stated Dr. Joachim Schulze, Head of Uhde GmbH's BioTechnology Division.

Succinic Acid has been recognized by both government organizations and the chemical industry as one of the most promising biochemicals that can be produced from renewable feedstocks to replace a wide range of petroleum-based chemicals. Myriant's renewable Succinic Acid offers cost competitive performance, reduced price volatility and a significantly enhanced environmental footprint as compared to petroleum-based alternatives. Given Succinic Acid's versatility, it can be used in a wide range of applications including polymers, solvents, pharmaceuticals, food and pigments. Typical end products that can utilize renewable Succinic Acid include car components, computer and electronic casings, shoe soles and paints.

Uhde GmbH has a workforce of more than 4,900 employees worldwide and is a company in the Plant Technology business area of the ThyssenKrupp Group. The company's activities focus on the engineering and construction of chemical and other industrial plants in the following fields: fertilisers; electrolysis; gas technologies; oil, coal and residue gasification; refining technologies; organic intermediates, polymers and synthetic fibres; and also coke plant and high-pressure technologies. "We also provide our customers with professional services and comprehensive solutions in all areas of industrial plant operation. Details are available at www.uhde.eu"

With a world-renowned team of molecular biologists, engineers and chemists, Myriant utilizes proprietary technology to advance the development of low-cost cellulosic sugars for the sustainable commercialization of high-value specialty chemicals. The company's D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant is headquartered in Quincy, Massachusetts. Details are available at www.myriant.com.

    Contacts:
    Myriant - Samuel G. McConnell, Sr. VP, Corporate Development
    (617) 657-5207
    Uhde Corporation of America - Dr. Dennis Lippmann, Managing Director
    (412) 257-8277
    Uhde GmbH - Dr. Joachim Schulze, Head of BioTechnology Division
    +49 (3 41) 9 89-74612
       Dr. Detlef Markmann, Head of Corporate Communications
       +49 (2 31) 5 47-3813

SOURCE Myriant Technologies LLC


'/>"/>
SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
2. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
3. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. TOPAZ Technologies Announces SoBran Inc. as New Customer
7. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. Epeius Biotechnologies to Partner at BIO Investor Forum
10. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
11. OriGene Technologies Acquires Marligen Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):